María Llorián-Salvador

Dr. María Llorián-Salvador


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2022 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
MLMaría Llorián-Salvador
María Llorián-Salvador
EBEimear M. Byrne
Eimear M. Byrne
MSManon Szczepan
Manon Szczepan
KLKaris Little
Karis Little
MCMei Chen
Mei Chen
Heping XuHeping Xu
Heping Xu
Background: We previously reported higher plasma levels of complement fragments C3a and C5a in neovascular Age-related Macular Degeneration (nAMD) patients with macular fibrosis. This study aimed to understand whether complement activation contributes to the development of macular fibrosis and the underlying mechanisms involved. Methods: Complement activation was blocked using a C5 neutralizing antibody (BB5.1) in C57BL/6J mice after induction of subretinal fibrosis using the two-stage laser protocol. Fibrotic lesions were examined 10 days after the 2nd laser through fundus examination and immunohistochemistry. The expression of C5aR in fibrotic lesions and retinal pigment epithelial (RPE) cultures were examined by confocal microscopy. Primary murine RPE cells were treated with C3a or C5a (10–100 ng/mL) or TGF-β2 (10 ng/mL). Epithelial-to-mesenchymal transition (EMT) was assessed through various readouts. The expression of E-cadherin, vimentin, fibronectin, α-SMA, Slug, ERK/AKT and pSMAD2/3 were determined by Western blot and immunocytochemistry. Collagen contraction and wound-healing assays were used as functional readouts of EMT. The production of IL-6, TGF-β1, TGF-β2 and VEGF by RPE cells were determined by ELISA. PMX53 was used to block C5aR in RPE cultures and in vivo in mice with subretinal fibrosis. Results: Extensive C5b-9 deposition was detected at the site of subretinal fibrosis. BB5.1 treatment completely abrogated complement activation and significantly reduced subretinal fibrosis. C5aR was detected in RPE and infiltrating MHC-II+ cells in subretinal fibrosis. In vitro, RPE cells constitutively express C5/C5a and C5aR, and their expression was increased by TGF-β2 treatment. C5a but not C3a increased fibronectin, α-SMA, vimentin and Slug expression, and decreased E-cadherin expression in RPE cells. C5a treatment also increased the contractility and migration of RPE cells and enhanced the production of VEGF and TGF-β1/2. C5a treatment induced pSmad2/3 and pERK1/2 expression in RPE cells and this was blocked by PMX53. PMX53 treatment significantly reduced sodium fluorescein leakage in the subretinal fibrosis model, while collagen-I+ lesions only mildly reduced. Conclusions: Complement activation is critically involved in the development of subretinal fibrosis, partially through C5a–C5aR-mediated EMT in RPE cells. Targeting complement activation rather than C5a may be a novel approach for the management of macular fibrosis.

16 July 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
EBEimear Byrne
Eimear Byrne
MLMaría Llorián-Salvador
María Llorián-Salvador
MTMiao Tang
Miao Tang
AMAndriana Margariti
Andriana Margariti
MCMei Chen
Mei Chen
Heping XuHeping Xu
Heping Xu
Blood–retinal barrier (BRB) dysfunction underlies macular oedema in many sight-threatening conditions, including diabetic macular oedema, neovascular age-related macular degeneration and uveoretinitis. Inflammation plays an important role in BRB dysfunction. This study aimed to understand the role of the inflammatory cytokine IL-17A in BRB dysfunction and the mechanism involved. Human retinal pigment epithelial (RPE) cell line ARPE19 and murine brain endothelial line bEnd.3 were cultured on transwell membranes to model the outer BRB and inner BRB, respectively. IL-17A treatment (3 days in bEnd.3 cells and 6 days in ARPE19 cells) disrupted the distribution of claudin-5 in bEnd.3 cells and ZO-1 in ARPE19 cells, reduced the transepithelial/transendothelial electrical resistance (TEER) and increased permeability to FITC-tracers in vitro. Intravitreal (20 ng/1 μL/eye) or intravenous (20 ng/g) injection of recombinant IL-17A induced retinal albumin leakage within 48 h in C57BL/6J mice. Mechanistically, IL-17A induced Janus kinase 1 (JAK1) phosphorylation in bEnd.3 but not ARPE19 cells. Blocking JAK1 with Tofacitinib prevented IL-17A-mediated claudin-5 dysmorphia in bEnd.3 cells and reduced albumin leakage in IL-17A-treated mice. Our results suggest that IL-17A can damage the BRB through the activating the JAK1 signaling pathway, and targeting this pathway may be a novel approach to treat inflammation-induced macular oedema.

Verified
Journal Article
Open access
PDF file
EBEimear Byrne
Eimear Byrne
MLMaría Llorián-Salvador
María Llorián-Salvador
TLTimothy J. Lyons
Timothy J. Lyons
MCMei Chen
Mei Chen
Heping XuHeping Xu
Heping Xu
We have previously reported that inhibition of the Janus kinase 1 (JAK1) signaling ameliorates IL-17A-mediated blood-retinal barrier (BRB) dysfunction. Higher levels of IL-17A have been observed in the blood and intraocular fluids in patients with diabetic retinopathy (DR), in particular those with diabetic macular oedema. This study aimed to understand whether JAK1 inhibition could prevent BRB dysfunction in db/db mice, a model of type 2 diabetes (T2D). An in vitro study showed that high glucose treatment disrupted the junctional distribution of claudin-5 in bEnd3 cells and ZO-1 in ARPE19 cells and that tofacitinib citrate treatment prevented high glucose-mediated tight junction disruption. Albumin leakage, accompanied by increased levels of the phosphorylated form of JAK1 (pJAK1), was observed in three-month-old db/db mice. Treatment of two-and-a-half-month-old db/db mice with tofacitinib citrate for two weeks significantly reduced retinal albumin leakage and reduced pJAK1 expression. pJAK1 expression was also detected in human DR retina. Our results suggest that JAK1 inhibition can ameliorate BRB dysfunction in T2D, and JAK1 inhibitors such as tofacitinib citrate may be re-purposed for the management of diabetic macular oedema.

27 October 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
DPDaniel Pérez-Martínez
Daniel Pérez-Martínez
MCMaría Jose Canz
María Jose Canz
ETElisabet Torras-Peyrotón
Elisabet Torras-Peyrotón
AAAnna Alvarez-Guaita
Anna Alvarez-Guaita
LRLorena Ramos-Pérez
Lorena Ramos-Pérez
MLMaría Llorián-Salvador
María Llorián-Salvador
Introduction: Type 2 diabetes mellitus (T2D) is characterized by chronic, low-grade inflammation and immune dysregulation, contributing to insulin resistance and metabolic complications. Regulatory T cells (Tregs) are key modulators of immune homeostasis, and their therapeutic expansion has shown promise in limiting inflammation. Here, we investigated whether in vivo Treg expansion could modulate metabolic and inflammatory responses in T2D in a sex-specific manner. Methods: Male and female db/db and db/+ mice received intraperitoneal injections of IL-2/anti-IL-2 (JES6-1) complexes for six weeks to induce endogenous Treg expansion. Body weight, blood glucose, and insulin levels were monitored to calculate HOMA-IR. Plasma inflammatory and anti-inflammatory mediators (CRP, adiponectin, IL-10, IL-13, CCL3) were quantified by bead-based immunoassays. Hepatic triglycerides and gene expression of Foxp3, F4/80, Pparγ, Il10 and Il13 were analyzed by biochemical assays, western blot, and RT-qPCR. Results: Treg expansion reduced weight gain in db/db mice independently of food intake. Female mice displayed lower HOMA-IR, decreased CRP, and increased adiponectin, IL-10, and IL-13 levels, whereas males showed limited improvement. Hepatic triglycerides and F4/80 expression were reduced after Treg expansion, with restored Foxp3 and elevated Il10/Il13 expression, indicating diminished hepatic inflammation. Conclusion: Endogenous Treg expansion exerts sex-specific metabolic and anti-inflammatory benefits in db/db T2D mice, with females showing greater improvements in insulin resistance, inflammation, and hepatic lipid metabolism. These findings support Treg-based immunomodulation as a potential therapeutic approach for T2D and emphasize the need for sex-specific considerations in future research.

8 May 2025 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
AAAna I. Arroba
Ana I. Arroba
EBEleni Beli
Eleni Beli
JHJose R. Hombrebueno
Jose R. Hombrebueno
MLMaría Llorián-Salvador
María Llorián-Salvador
The rod visual pathway undergoes significant structural remodeling with age. Changes are evident at the rod photoreceptor level, including shortening of outer segments, reduced opsin expression and axonal retraction. Second order neurons (including bipolar and horizontal cells), undergo compensatory sprouting, yet this remodeling appears insufficient to prevent age-related decline. In a longitudinal study of the aging mouse retina, Gierke et al. describe age-related changes in rod and cone photoreceptor ribbon synapses and postsynaptic neurons. Building on previous research [5,6], they demonstrate synaptic plasticity in photoreceptors during aging through the formation of ectopic synapses between photoreceptors and second-order neurons. Interestingly, they report that synaptic remodelling during aging was not associated with changes in the protein composition of ribbon synapses, but rather with an increase in mitochondrial size in photoreceptor terminals. These findings are significant not only for understanding photoreceptor decline and synaptic remodelling during aging, but also for conditions that may accelerate retinal aging including diabetes [7,8], where disrupted mitochondrial homeostasis has emerged as a key factor in photoreceptor synaptic decline [9].Age-related macular degeneration (AMD) is one of the most prevalent visual conditions associated with aging [3]. The pathogenesis of AMD is complex, with chronic inflammation playing a significant role, driven in part by microglial activation and cellular senescence, which exacerbate secretion of pro-inflammatory factors [10]. Among these, secreted phosphoprotein 1 (SPP1) has emerged as an important pathogenic mediator in inflammatory disorders [11][12][13][14] To better understand the role of SPP1 in AMD, Lei et al., report a single-cell sequencing study of the human macula neuroretina. Their findings show a dominant upregulation of pro-inflammatory over anti-inflammatory cytokines in retinal microglia from AMD patients. Furthermore, they demonstrate that SPP1 is the most elevated senescence-related cytokines in both wet and dry AMD, which is associated with the pro-inflammatory and phagocytic status of microglia. This study underscores the pathogenic role of SPP1 in AMD and highlights its potential as a therapeutic target for this devastating visual condition.While elevated intraocular pressure (IOP) is widely recognized as a major risk factor for glaucoma, aging independently contributes to ocular tissue vulnerability [15,16]. People affected by glaucoma exhibit increased autoantibody titers against several proteins including heat shock proteins (HSPs) [17]. HSPs maintain proteostasis by assisting in protein folding and degradation of misfolded proteins [18]. In glaucoma, elevated HSP27 expression and serum autoantibodies have been observed [17], while intravitreal HSP27 injection induces RGC cell loss independent of IOP [17]. Building on these findings, Erl et al., sought to investigate whether age increases susceptibility to HSP27-induced glaucomatous damage. In their study, young (1-2 months) and older (7-8 months) mice received intravitreal injections of HSP27. No significant age-dependent differences were observed in the extent of RGC and optic nerve degeneration. However, older mice demonstrated a slightly heightened inflammatory response, as indicated by increased microglial activation. Further research on aged mice (16-18 month old) [19], is necessary to fully understand the role of HSP27 in age-related neurodegeneration and its potential contribution to glaucoma progression.Extracellular matrix (ECM) is also affected by aging, leading to structural and biochemical alterations [20], which may compromise the homeostasis of retinal neurons. Accordingly, ECM alterations have emerged as important contributors of retinal disease, including AMD and diabetic retinopathy [21,22]. Muller glia are critical for extracellular matrix remodelling [23], yet this function declines with age as shown by reduced production of ECM components and altered expression of matrix metalloproteinases. To further advance knowledge on this exciting research area, Prieto-Lopez et al, present a comprehensive review of the role of Muller glia in shaping the ECM under physiological and pathological conditions. They also review the suitability of several biomaterials that mimic retinal ECM, positioning this review as a useful resource for refining in vitro platforms aimed at modelling ECM alterations in health and disease.As the aging population and life-expectancy continues to grow, it is imperative to deepen our understanding of the molecular and cellular processes underpinning retinal aging and disease progression. Advancing this knowledge will offer new therapeutic avenues aimed at preserving vision, mitigate the healthspan-lifespan gap and alleviate the societal challenges posed by age-related vision loss. We hope that this Research Topic has contributed meaningfully to clarifying key aspects of retinal aging, while highlighting the complex, multifactorial nature of age-related changes in both the healthy and diseased eye.